Gate2Brain Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$1.15M
- Investors
-
11
Gate2Brain General Information
Description
Developer of a novel technology platform designed to deliver therapeutics across biological barriers. The company's platform focuses on the development of therapeutics that efficiently cross biological barriers, such as the blood-brain barrier, using a radically innovative peptide-based patented technology platform, enabling clients to cure rare pediatric cancers.
Contact Information
Website
www.gate2brain.comCorporate Office
- Barcelona Science Park
- Baldiri Reixac, 4-8 Torre I
- 08028 Barcelona
- Spain
Corporate Office
- Barcelona Science Park
- Baldiri Reixac, 4-8 Torre I
- 08028 Barcelona
- Spain
Gate2Brain Timeline
Gate2Brain Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Seed Round | $1.15M | Completed | Pre-Clinical Trials | |||
| 11. Corporate | 03-Jun-2026 | Completed | Pre-Clinical Trials | |||
| 10. Accelerator/Incubator | 30-Oct-2023 | Completed | Pre-Clinical Trials | |||
| 9. Grant | 24-Apr-2023 | Completed | Pre-Clinical Trials | |||
| 8. Grant | 05-Oct-2022 | Completed | Pre-Clinical Trials | |||
| 7. Accelerator/Incubator | 13-Apr-2022 | Completed | Pre-Clinical Trials | |||
| 6. Accelerator/Incubator | 01-Jan-2022 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 27-Dec-2021 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | 09-Jul-2021 | $5.97K | $680K | Completed | Pre-Clinical Trials | |
| 3. Accelerator/Incubator | 15-Jul-2020 | $563K | $674K | Completed | Pre-Clinical Trials |
Gate2Brain Patents
Gate2Brain Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023317659-A1 | Site-specific modification by a bbb-shuttle of antibody-based entities for crossing the blood-brain barrier | Pending | 01-Aug-2022 | ||
| EP-4565281-A1 | Site-specific modification by a bbb-shuttle of antibody-based entities for crossing the blood-brain barrier | Pending | 01-Aug-2022 | ||
| WO-2024028282-A1 | Site-specific modification by a bbb-shuttle of antibody-based entities for crossing the blood-brain barrier | Inactive | 01-Aug-2022 | ||
| AU-2023242296-A1 | Peptidic water-soluble delivery system of anticancer drugs | Pending | 28-Mar-2022 | ||
| EP-4499150-A1 | Peptidic water-soluble delivery system of anticancer drugs | Pending | 28-Mar-2022 | A61K47/6907 |
Gate2Brain Signals
Gate2Brain Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Shilpa Medicare | Corporation | Minority | ||
| EIT Health | Accelerator/Incubator | |||
| European Innovation Council | Accelerator/Incubator | Minority | ||
| i4KIDS | Accelerator/Incubator | |||
| Grit Female Accelerator | Accelerator/Incubator |
Gate2Brain FAQs
-
When was Gate2Brain founded?
Gate2Brain was founded in 2020.
-
Where is Gate2Brain headquartered?
Gate2Brain is headquartered in Barcelona, Spain.
-
What is the size of Gate2Brain?
Gate2Brain has 12 total employees.
-
What industry is Gate2Brain in?
Gate2Brain’s primary industry is Drug Discovery.
-
Is Gate2Brain a private or public company?
Gate2Brain is a Private company.
-
What is Gate2Brain’s current revenue?
The current revenue for Gate2Brain is .
-
How much funding has Gate2Brain raised over time?
Gate2Brain has raised $10M.
-
Who are Gate2Brain’s investors?
Shilpa Medicare, EIT Health, European Innovation Council, i4KIDS, and Grit Female Accelerator are 5 of 11 investors who have invested in Gate2Brain.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process